Background 5-HT 3 antagonists have been shown to be effective in relieving the symptoms of irritable bowel syndrome with diarrhoea (IBS-D). Using a recently validated magnetic resonance imaging (MRI) method, we have demonstrated reduced fasting small bowel water content (SBWC) in IBS-D associated with accelerated small bowel transit. We hypothesized that slowing of transit with ondansetron would lead to an increase in SBWC by inhibiting fasting motility.
SUMMARY
Background 5-HT 3 antagonists have been shown to be effective in relieving the symptoms of irritable bowel syndrome with diarrhoea (IBS-D). Using a recently validated magnetic resonance imaging (MRI) method, we have demonstrated reduced fasting small bowel water content (SBWC) in IBS-D associated with accelerated small bowel transit. We hypothesized that slowing of transit with ondansetron would lead to an increase in SBWC by inhibiting fasting motility.
Aim
To assess the effects of ondansetron compared with placebo in healthy volunteers on SBWC and motility in two different groups of subjects, one studied using MRI and another using manometry.
Methods
Healthy volunteers were given either a placebo or ondansetron on the day prior to and on the study day. Sixteen volunteers underwent baseline fasting and postprandial MRI scans for 270 min. In a second study, a separate group of n = 18 volunteers were intubated and overnight migrating motor complex (MMC) recorded. Baseline MRI scans were carried out after the tube was removed.
INTRODUCTION Serotonin [5-hydroxytryptamine (5-HT)] is a key signalling molecule in gastrointestinal physiology acting via a range of different 5-HT receptors to stimulate secretion, sensation and motility. [1] [2] [3] [4] [5] Ondansetron, a 5-HT 3 receptor antagonist inhibits the nausea and vomiting associated with chemotherapy. An important side effect in such patients is constipation. This has been exploited therapeutically in irritable bowel syndrome with diarrhoea (IBS-D) patients in whom 5HT 3 receptor antagonists improve symptoms, reducing stool frequency, urgency and abdominal discomfort while increasing stool consistency. 6 Other 5HT 3 receptor antagonists, granisetron 7 and alosetron inhibit the colonic response to feeding and ondansetron inhibits the excessive postprandial increase in colonic tone characteristic of carcinoid syndrome. 8 Although ondansetron slows colonic transit, 9, 10 its effect on human small bowel motility and secretion remains unclear.
Activation of 5-HT 3 receptors stimulates anion secretion 11 and motility, an effect blocked by 5-HT 3 receptor
antagonists, but the relative importance of these effects in ondansetron's antidiarrhoeal actions in man remains uncertain. One key weakness in studies to date has been a lack of data on the effect on intestinal secretions, largely due to technical difficulties associated with the intestinal perfusion studies needed to answer such questions, which inhibit their use in patients.
We have recently validated a novel non-invasive magnetic resonance imaging (MRI) technique for assessing small bowel water content (SBWC) 12, 13 which is highly acceptable to patients. Postprandially, the SBWC depends on the balance between delivery of fluid via gastric emptying and the removal of fluid by either propulsion into the colon or absorption. In contrast, in the fasting state, fluid flow is intermittent, with low basal levels interrupted periodically by increased flow driven by the MMC, 14, 15 which propels residual fluid distally, ultimately into the colon. Our aim was to understand further the mode of action of ondansetron which, our clinical experience over the last 4 years suggests, is highly beneficial to some IBS-D patients (unpublished). We hypothesized that slowing of fasting small bowel transit with ondansetron would lead to an increase in fasting small bowel fluid. We therefore performed a randomized, double-blind, placebo-controlled, two-way cross-over trial of ondansetron versus placebo to assess its effect on the fasting and postprandial SBWC. As our results showed an increase in fasting SBWC, we performed a second RCT to examine the effect of ondansetron on fasting small intestinal motility to see whether the change in small bowel water was due to an inhibition of fasting motility.
MATERIALS AND METHODS
We carried out two separate randomized, double-blind, placebo-controlled, two-way cross-over studies in healthy volunteers. These studies were approved by the Local Research Ethics Committee and by the Institution's R&D department. All volunteers gave informed written consent before participating and the studies were carried out according to Good Clinical Practice standards. Web-based, computerized, block randomizations were provided by the local Clinical Trials Support Unit and the codes were broken only after locking the databases. The drug packs containing drug or matched placebo were manufactured according to Good Manufacturing Practice.
The inclusion criteria for the volunteers were men or women, healthy volunteers, 18-65 years old, of normal body mass index. Exclusion criteria were pregnancy and breastfeeding, any history of gastrointestinal illness, use of medication known to affect gastrointestinal transit, such as opiates and anticholinergics, and unsuitability for MRI scanning (such as having any metal implants or pacemakers). The subjects were asked to abstain from any medication that is likely to alter gut motility for 24 h (inhaler medications for asthma and the oral contraceptive pill were allowed), alcohol for 24 h, caffeine for 18 h and strenuous exercise for 24 h prior to the study days. They were also asked not to consume food or drink since the previous evening (except for a small cup of water on waking up). They were asked to fill an eligibility questionnaire on the morning of each study day.
Study 1: Magnetic resonance imaging
Eighteen healthy volunteers were recruited for this study. Two subjects (one man and one woman) were excluded, as one did not comply with the fasting criteria (as shown by presenting with a full stomach at the baseline MRI scans) and the other suffered from diarrhoea before the dosing period (as shown by the stool diaries). Hence, 16 subjects completed the entire study. They were eight women and eight men (age 20.7 AE 0.2 years, body mass index 22.8 AE 0.6 kg ⁄ m 2 ). Each volunteer was enrolled for a 2-day study period on two separate occasions, approximately 1 week apart.
The volunteers received either 8 mg ondansetron t.d.s. or identical looking placebo on day 1. On day 2, they presented at the MRI unit at 08:00 hours after an overnight fast. Then, they received a further dose of either 16 mg ondansetron or placebo followed by 50 mL water and 1 h later, they underwent a set of fasting MRI scans (as shown schematically in the top diagram of Figure 1 ).
After their baseline MRI scans, the subjects were given a standard 362 kcal rice pudding meal comprising 220 g of creamed rice pudding (J. Sainsbury's, London, UK), 34 g of seedless raspberry jam (Robertson's, Addlestone, Surrey, UK) and 15 g of coarse wheat bran, taken with a glass of 100 mL of orange juice from concentrate (J. Sainsbury's) as previously used. 13, 16 The meal provided 71.4 g carbohydrate and 4.38 g fat. After the meal, the subjects underwent serial imaging at 45-min intervals until t = 270 min while subjective feelings of the volunteers' fullness, hunger, appetite, nausea, abdominal pain and bloating were assessed using self-assessment visual analogue symptoms scales. They also completed a Bristol Stool Diary 17 for 1 week beginning 4 days before scanning on each occasion. The MRI scanning was carried out using a 1.5 T Philips Achieva scanner (Best, Netherlands). Each volunteer was positioned supine in the scanner with a four-element, parallel imaging body coil wrapped around the abdomen. After acquiring a scout scan to locate the position of the abdominal organs, a range of MRI scans were taken. A balanced gradient echo (balanced turbo field echo, BTFE) sequence, with echo time TE = 1.19 ms and repetition time TR = 2.4 ms), was used to assess gastric emptying. This comprised 20 transverse images with an in-plane resolution of 1.56 mm · 1.56 mm and slice thickness of 10 mm, with no gap between slices. A single shot, fast spin echo sequence [similar to that used for MR cholangiopancreatography (MRCP)] with effective TE = 320 ms was used to assess SBWC. 12 This comprised 24 coronal images with in-plane resolution interpolated to 0.78 mm · 0.78 mm and a slice thickness of 7 mm, with no gap between slices (acquired voxel size = 1.56 · 2.83 · 7 mm 3 ). A dual gradient echo imaging sequence (dual-echo fast field echo, FFE) with TE1 = 2.3 ms, TE2 = 4.6 ms and TR = 158 ms was used to visualize the anatomy. This comprised 24 coronal plane and 45 transverse images with in-plane resolution 1.76 mm · 1.76 mm and a slice thickness of 7 mm, with no gap between slices. Each image set was acquired on a single expiration breathhold, the duration of which varied between 13 and 24 s depending on the sequence. Including set-up and imaging, the volunteers spent approximately 6 min inside the magnet for every time point, spending the rest of the time sitting upright in an adjacent room. Figure 2 shows relevant examples of these MRI images. O On nd da an ns se et tr ro on n a an nd d s sm ma al ll l b bo ow we el l w wa at te er r c co on nt te en nt t Aliment Pharmacol Ther 2010; 32: 655-663Study 2: Manometry Twenty-five healthy volunteers were recruited for this study. Seven of these withdrew: five due to discomfort with the intubation procedure on the first occasion, one due to equipment failure and one due to changes in their commitments. Hence, 18 subjects completed the entire study. They were eight women and 10 men (age 20.4 AE 0.7 years, body mass index 22.7 AE 0.6 kg ⁄ m 2 ). Each volunteer was enrolled for a 3-day study period on two separate occasions, approximately 1 week apart.
The subjects received either 8 mg ondansetron t.d.s. or identical looking placebo on days 1 and 2. At 12:00 hours on day 2, the volunteers attended at the study unit having eaten nothing since breakfast, which was taken before 08:00 hours. Here, they were intubated in the seated position with a calibrated gastrointestinal catheter. The catheter used was a six-channel, solid-state gastrointestinal transducer catheter with a steel weighted tip (Gaeltec; Dunvegan, Isle of Skye, Scotland) and an outer diameter of 3.5 mm. Recording ports were positioned at 5, 10, 20, 22.5, 25 and 27.5 cm from the tip of the catheter. A local anaesthetic spray (Xylocaine spray; AstraZeneca, Sodertalje, Sweden) was administered and they were allowed to sip water to aid the passage of the catheter. The catheter was allowed to pass to the duodenum by normal propagating activity (subjects were asked to recline on their right side to assist this) and its position was confirmed by observing appropriate contractile activity (gastric or duodenal). Adjustments could then be made as necessary to the position of the catheter. Once correctly positioned, the tube was taped to the nose and the proximal end connected to a Flexilog 3000 ambulatory recorder (Oakfield Instruments Ltd, Eynsham, Oxon, UK). Subjects were then allowed to return home with a standard meal consisting of 450 g of chicken lasagne (J. Sainsbury's), 42 g of wholegrain crackers (J. Sainsbury's) and 40 g of mature cheddar (Cathedral City; Dairy Crest Ltd, Shropshire, UK), with a total caloric content of 809 kcal. They were instructed to consume their meal before 19:00 hours. This meal was chosen to ensure complete digestion prior to going to bed and volunteers were then asked to refrain from eating until the following morning, allowing the overnight fasting MMC frequency to be recorded. They were allowed to drink a small cup of water on waking up.
The subjects presented at the MRI unit at 07:30 hours on day 3, and the catheter was withdrawn and the recordings downloaded. They then received a final dose of 16 mg ondansetron or placebo followed by 50 mL of water. One hour after dosing, a fasting set of MRI scans was performed as described above for Study 1 and shown schematically in the bottom diagram of Figure 1 .
Volunteers also completed a Bristol Stool Diary for 2 days before and 2 days during ondansetron or placebo treatment.
Data analysis
Measurements of the volume of the gastric contents were carried out on the axial images by manually tracing a region of interest around the meal within the stomach on each image slice using ANALYZE6 software (Biomedical Imaging Resource, Mayo Foundation, Rochester, MN, USA) and summing across the slices to determine the total volume at different time points. The surrounding organs and gastrointestinal gas were easily discriminated and excluded from the region of interest. The time for half emptying was calculated from the plots of volume against time.
The SBWC images were analysed as previously described. 12 Briefly, regions of interest were drawn manually around the small bowel on each of the MRCP images excluding regions such as the stomach, gall bladder and blood vessels using in-house software on an IDL platform (IDL 5.4; Research Systems Inc., Boulder, CO, USA). The software then calculated the number of voxels (a 3-dimensional data set) in each of the regions of interest with an intensity above a threshold calibrated using the corresponding subject's cerebrospinal fluid.
12
Antroduodenal motility data were downloaded from the Flexilog 3000 recorders into the Flexisoft III Data Display and Analysis software, Version 2, 6.0 (Sandhill Scientific -UK Ltd, Eynsham, Oxon, UK) for an initial assessment and then exported into dedicated antroduodenal analysis software (MMS -Medical Measurement Systems BV, Enschede, the Netherlands).
Motion artefacts (such as simultaneous pressure rises occurring at all transducers with similar and identical duration) were eliminated and contractions were identified in all channels. A contraction was deemed valid if it exceeded the baseline threshold of 10 mmHg. MMCs were identified as periods of regular contractions exceeding the 10 mmHg threshold at the maximum frequency. Phase 3 contractions lasting <2 min or with an amplitude of <10 mmHg were excluded. A number of channel markers were used allowing assessment from 23:00 hours until removal of the catheter of the number of the fasting MMC phase 3 contractions together with overall motility as assessed by the AUC (mmHg s) and Motility Index [ln((number of contraction · sum contraction amplitude) + 1)] for the total recording period.
Power and statistical analysis
The primary endpoint was the effect of ondansetron on fasting SBWC. On the basis of previous data, 13 we could calculate that to be able to detect a one standard deviation increase in fasting SBWC with a power of 90%, we would need 13 paired studies using a = 0.05. We chose to study 18 to allow for dropouts or incomplete data. Statistical analysis was carried out using PRISM 4 (GraphPad Software Inc., San Diego, CA, USA). Normality of the data was tested using Shapiro-Wilk's test. Paired comparisons were performed using two-tailed Student's t-test for normal and two-tailed Wilcoxon's test for non-normal data. Comparisons between groups were performed using two-tailed unpaired t-test or MannWhitney's U-test respectively. Two-way analysis of variance was used to assess the significance of differences over time and for this analysis non-normal data was Log transformed. Post hoc assessments were then performed using Bonferroni correction. The data are expressed as mean (AES.E.M.) when normally distributed and as median (interquartile range) when not normally distributed.
RESULTS
Ondansetron was well tolerated with no adverse events on both studies. All subjects in Study 1 tolerated the test meal and serial MRI scanning procedures without difficulty. High quality images as shown in Figure 2 were obtained in all subjects and no images were rejected during the gastric emptying and small bowel water analysis. The procedures for the manometry Study 2 were more demanding than that of Study 1. From the initial 25 subjects recruited, dropouts, equipment failures and overnight changes in the positioning of the tube reduced the available data to 18 subjects for the fasting MRI imaging, 17 subjects for the antral traces and 14 for the duodenal ones. Figure 3 shows the fasting baseline (t = )45 min) SBWC individual data points. This was significantly higher for ondansetron, median(IQR) 227(194-324) mL than for placebo 167(103-209) mL, P < 0.0007.
Study 1: Magnetic resonance imaging
The time courses of SBWC are shown in Figure 4 . These showed a triphasic pattern which matches well with the one observed previously with the same meal in healthy subjects. 13 Postprandially, despite the stomach emptying half of its contents into the small bowel over the first 90 min, SBWC fell significantly to median 17 (9-34) mL at 90 min for placebo (P < 0.001) and to 14(6-52) mL for ondansetron (P < 0.001). There was then a rise during a second phase between 90 and 180 min, during which there were no significant differences between drug and placebo. SBWC reached a plateau in a third phase between 180 and 270 min towards the end of which the two curves diverged, although this difference was not statistically significant when corrected for multiple comparisons. There was no overall effect of ondansetron on gastric emptying (two-way ANOVA for effect of drug, P < 0.2). The time to half empty the gastric contents (T1 ⁄ T2) was the same between ondansetron (89 AE 6 min) and placebo (88 AE 5 min), P < 0.9. Only a small effect of ondansetron was detected on the area under the gastric emptying curve, which was smaller for the ondansetron (43 753 AE 1895 mL ⁄ min) than for the placebo (47 313 AE 2343), P < 0.05.
The symptom scores for fullness, hunger, appetite, abdominal pain, nausea and bloating showed no significant differences between ondansetron and Placebo. Daily stool frequency and average stool consistency on the 2 days prior to the scanning day were not significantly different between ondansetron and placebo. There was no effect of this short period of dosing on mean daily stool frequency during the 2 days postdosing, which was 1.5 AE 0.2 bowel movements on placebo and 1.6 AE 0.2 on ondansetron (P < 0.7). There was no significant difference in average stool consistency as measured from the Bristol Stool Form score, which was 3.1 AE 0.3 on placebo and 3.8 AE 0.3 on ondansetron (P < 0.1).
Study 2: Manometry
Ondansetron reduced all the antroduodenal motility parameters investigated, although only the difference in the Motility Index reached statistical significance (Table 1) .
These subjects were also scanned fasted immediately after removal of the nasoduodenal tube. A weak (Spearman's r = )0.29) negative correlation between fasting SBWC and Motility Index was observed, although this was not significant (P < 0.1). However, in contrast with Study 1, no difference in fasting SBWC between ondansetron (67 AE 12 mL) and placebo (74 AE 11 mL) was found (P < 0.6).
However, comparing the fasting SBWC of the two studies ( Figure 5) shows that irrespective of the study arm, the SBWC after overnight intubation 55(35-97) mL was substantially lower than for the group that was not intubated 203(153-279) mL, Mann-Whitney's P < 0.0001. The average Global Well Being scores from the Bristol Stool Questionnaires were also significantly lower for the intubated group (6.6 AE 0.4) than for the non-intubated group (8.4 AE 0.4), P < 0.0002 indicating that the intubation procedure was stressful.
DISCUSSION
Our main finding that ondansetron significantly increased fasting SBWC in a group of healthy volunteers could be due to either an increase in small bowel secretion or a reduction in fasting small bowel propulsive motility. It is unlikely that ondansetron stimulates secretion as data in both animals and man suggest to the contrary that they inhibit postprandial pancreatic and intestinal secretions. [18] [19] [20] [21] [22] [23] We feel that it is more likely that the increase in fasting SBWC is due to reduced fasting small bowel motility. Ondansetron is known to inhibit colonic motility 24 and the MMC 25 at least in rodents.
That this effect is mediated via 5-HT 3 receptors in man is also supported by our previous finding that 5-HT 3 agonists appear to have the opposite effect, increasing MMC frequency and accelerating small bowel transit in the postprandial state. 26 We carried out Study 2 to test the hypothesis that ondansetron would inhibit MMCs in humans. We found in Study 2 that ondansetron significantly reduced the antroduodenal Motility Index (P < 0.04) and it also reduced the number of peaks per minute, the peak amplitude and the area under the curve of the fasting MMCs, although these differences did not reach statistical significance. This finding agrees with previous studies in which 5-HT administration increased the frequency of the MMC, 27, 28 whereas an antagonist of 5-HT 3 receptors would be expected to reduce MMC frequency 25, [29] [30] [31] [32] particularly via action on interneurones of the myenteric plexus, which are involved in the initiation of MMCs. 33 This inhibitory effect is consistent with the fact that ondansetron was originally developed to inhibit the nausea induced by chemotherapeutic agents, particularly cisplatinum, which releases large amounts of serotonin from mucosal enterochromaffin cells and induces vomiting by stimulating 5HT 3 receptors on the vagus nerve. This inhibitory effect is also associated with slowing of colonic transit in man 9 that may allow increased time for absorption and contribute to an increase in stool consistency, which was a striking benefit in many trials of 5HT 3 receptor antagonists. 34 Ondansetron appeared to have a lesser effect postprandially than when fasting. Although SBWC was lower on ondansetron from 180 to 270 min, postprandially this difference was not significant possibly because although the antisecretory effects of ondansetron reduce SBWC, its antimotility effects may produce the opposite effect. Another factor to consider is that both 5HT 3 and 5HT 4 receptors are important in controlling human jejunal secretion and peristalsis 35, 36 thereby reducing the effect of a pure 5HT 3 antagonist like ondansetron. The increased fasting small bowel water did not appear to be associated with symptoms like bloating in our volunteers and in one clinical trial, ondansetron did not worsen bloating. 37 Our technique only measures volume, although if combined with orocaecal transit time, a flow index can be calculated as we did in a previous study, 13 but this measurement was not made in the current study.
We found a striking difference between the fasting SBWC of the subjects in the MRI feeding Study 1 and that in those in the manometry Study 2. The fasting small bowel water was found to be very much lower (P < 0.0001) amongst the intubated subjects. We feel the failure to reproduce the findings of Study 1 as regards the effect of ondansetron was because this effect of intubation was so much stronger than the drug effect.
Gastrointestinal intubation has been shown previously to affect gastrointestinal function, delaying gastric emptying and accelerating small bowel transit. 38 It seems likely that the fall in small bowel water is due to increased propulsive motility induced by mechanoceptor-mediated stimulation by the catheter. Mechanical stimulation of the mucosa is known to stimulate secretions via serotonin release 18 and to stimulate propulsive motility via 5-HT 3&4 receptor stimulation. 39 Nausea and stress induced by intubation also have a role in accelerating small bowel transit. 40, 41 Stress from the intubation procedures or from disturbed sleep due to the presence of the tube might therefore have had an influence on the amount of SBWC. We did not assess formally the level of stress of the subjects in the manometry Study 2, although anecdotally they all found it unpleasant. We did assess Global Well Being and consistent with our anecdotal impression, these subjects did have significantly reduced scores compared with the group of Study 1. It is interesting to note a possible analogy with patients with IBS-D, a group in which the role of stress and anxiety is important and who were recently O On nd da an ns se et tr ro on n a an nd d s sm ma al ll l b bo ow we el l w wa at te er r c co on nt te en nt t Aliment Pharmacol Ther 2010; 32: 655-663
shown to have reduced fasting small bowel water and accelerated small bowel transit. This was found to correlate negatively with anxiety. 13 A unique feature of our MRI studies is the ability to describe the physiological changes in an otherwise undisturbed SBWC after feeding. It can also provide information about the overall impact of changes in small bowel motility, absorption and secretion unlike intubated studies that assess motility at only a few discrete points in the bowel and absorption from a limited segment of bowel. The use of MRI to assess gastric emptying has been documented in the literature [42] [43] [44] [45] and this has recently been used in conjunction with validated MRI measurements of SBWC. 12 This allows an accurate assessment of both gastric volumes and SBWC, which yields novel insights into gastrointestinal events, physiology and disease. 13 We scanned three individuals per session and acquired individual scans at 45 min intervals, a time sufficient to characterize the time courses while keeping costs reasonable. We performed these initial studies in healthy volunteers as they are a much more homogenous group than IBS-D patients, hence making it easier to show a pharmacological effect with small numbers. We are currently in the process of performing a much larger randomized placebo-controlled study (RCT) of ondansetron in IBS-D to see if these findings can be reproduced in patients. Although this is currently not a licensed indication, we have been using ondansetron for severe IBS-D for some years at doses ranging from 4 mg daily to 8 mg t.d.s and we find that those who do respond do so in the lower dose range. Of course, definitive recommendations must await the results of our current RCT. The MRI technique was well tolerated and provided novel insights into the action of this drug and could be a marker of those who would respond to the drug. It could be applied to patient studies of other conditions such as coeliac disease and lactose intolerance in which increased small bowel water has been described. It could also be used to study the mode of action of a range of new drugs designed to alter secretions and motility such as lubiprostone, linaclotide, 5-HT 3 antagonists, opioids and 5-HT 4 agonists. The time and effort that it takes to process the large amount of data collected during serial MRI studies is a significant burden. However, current improvements in semi-automated image processing and an optimized and reduced scanning schedule will help broaden the use of these functional GI MRI techniques. Although currently expensive, as experience with the technique grows, it is highly likely that shorter scanning protocols will reduce costs further so that they become comparable in price with other investigations such as manometry or endoscopy.
